CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

February 12, 2024

https://www.globenewswire.com/news-release/2024/02/12/2827467/0/en/CervoMed-Publishes-Positive-Results-from-AscenD-LB-Phase-2a-Trial-in-Peer-Reviewed-Journal-that-Supports-the-Therapeutic-Potential-of-Neflamapimod-in-Dementia-with-Lewy-Bodies.html

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.